Want to see TSE:DMED full AI Analyst Report?
DMED Stock Chart & Stats
C$0.06
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.06
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.25
Previous CloseN/A
Volume16.98K
Average Volume (3M)274.25K
Market Cap
C$5.92M
Enterprise ValueC$4.90
Total Cash (Recent Filing)C$293.76K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta2.42
Next Earnings
Feb 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding131,559,310
10 Day Avg. Volume155,777
30 Day Avg. Volume274,252
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-21.78
Price to Sales (P/S)0.00
P/FCF Ratio-29.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Reported DebtThe absence of reported debt limits direct leverage and interest-burden risk, preserving some flexibility compared with a similarly loss-making company carrying borrowings. However, this benefit is only a partial offset because the business still has negative equity and ongoing funding needs.
Cash Losses Track Net LossesCash losses broadly matching reported net losses suggests that the weak results are not primarily caused by large non-cash accounting charges. This can make the financial position easier to assess, although the underlying cash burn remains a significant requirement for future funding.
Focused Health-Technology StrategyA defined focus on health technology and medical innovation gives DiagnaMed a clear strategic domain rather than an undifferentiated corporate mandate. That focus could support specialized product development and partnerships over time, although the pack does not show commercial traction yet.
Bears Say
No Reported RevenueThe absence of reported revenue indicates that the company has not yet demonstrated commercial monetization or a recurring operating base. Without sales, funding must support development and corporate activity, while future earnings depend on converting the innovation strategy into actual customer demand.
Worsening Net LossesLosses have widened materially across the reported periods, showing that operating costs are increasing faster than the company can generate income. Persistent negative operating profit weakens the prospect of near-term self-sufficiency and raises the amount of capital required to sustain development.
Persistent And Accelerating Cash BurnContinued negative operating and free cash flow means the business is consuming cash rather than funding operations internally. The larger TTM outflow versus 2025 suggests increasing financing pressure, which can constrain investment capacity and heighten dependence on external capital.
DiagnaMed Holdings Corp. News
DMED FAQ
What was DiagnaMed Holdings Corp.’s price range in the past 12 months?
DiagnaMed Holdings Corp. lowest stock price was C$0.03 and its highest was C$0.25 in the past 12 months.
What is DiagnaMed Holdings Corp.’s market cap?
DiagnaMed Holdings Corp.’s market cap is C$5.92M.
When is DiagnaMed Holdings Corp.’s upcoming earnings report date?
DiagnaMed Holdings Corp.’s upcoming earnings report date is Feb 02, 2027 which is in 135 days.
How were DiagnaMed Holdings Corp.’s earnings last quarter?
DiagnaMed Holdings Corp. released its earnings results on Jul 29, 2026. The company reported -C$0.01 earnings per share for the quarter.
Is DiagnaMed Holdings Corp. overvalued?
According to Wall Street analysts DiagnaMed Holdings Corp.’s price is currently Overvalued.
Does DiagnaMed Holdings Corp. pay dividends?
DiagnaMed Holdings Corp. does not currently pay dividends.
What is DiagnaMed Holdings Corp.’s EPS estimate?
DiagnaMed Holdings Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DiagnaMed Holdings Corp. have?
DiagnaMed Holdings Corp. has 131,559,310 shares outstanding.
What happened to DiagnaMed Holdings Corp.’s price movement after its last earnings report?
DiagnaMed Holdings Corp. reported an EPS of -C$0.01 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of DiagnaMed Holdings Corp.?
Currently, no hedge funds are holding shares in TSE:DMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DiagnaMed Holdings Corp.
Diagnamed Holdings Corp. engages in the development and commercialization of AI healthcare solutions. The company focuses on developing BRAIN AGE BRAIN HEALTH, a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It has a collaboration agreement with EIREX for the development and commercialization of EIREX’s novel modular carbon-free technology that extracts hydrogen from water. Diagnamed Holdings Corp. is headquartered in Toronto, Canada.
Technical Analysis
Diagnos
―
Rocket Doctor AI
―
Comprehensive Healthcare Systems Inc
―
UniDoc Health Corp
―
PanGenomic Health, Inc. Class A
―